Aptamer Group (APTA) Competitors GBX 1.10 0.00 (0.00%) As of 09/12/2025 11:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock APTA vs. SCLP, MPH, HVO, ORPH, REDX, ETX, SBTX, HEMO, COS, and C4XDShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Hemogenyx Pharmaceuticals (HEMO), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry. Aptamer Group vs. Its Competitors Scancell Mereo BioPharma Group plc (MPH.L) hVIVO Open Orphan Redx Pharma e-therapeutics SkinBioTherapeutics Hemogenyx Pharmaceuticals Collagen Solutions plc (COS.L) C4X Discovery Scancell (LON:SCLP) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Which has better valuation & earnings, SCLP or APTA? Scancell has higher earnings, but lower revenue than Aptamer Group. Scancell is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScancellN/AN/A-£6.75M-£0.02-439.90Aptamer Group£1.22M24.42-£14.17M-£0.00-392.86 Do insiders and institutionals hold more shares of SCLP or APTA? 0.9% of Scancell shares are owned by institutional investors. Comparatively, 4.3% of Aptamer Group shares are owned by institutional investors. 15.2% of Scancell shares are owned by insiders. Comparatively, 8.6% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is SCLP or APTA more profitable? Scancell has a net margin of 0.00% compared to Aptamer Group's net margin of -343.95%. Scancell's return on equity of 98.74% beat Aptamer Group's return on equity.Company Net Margins Return on Equity Return on Assets ScancellN/A 98.74% -45.28% Aptamer Group -343.95%-205.63%-44.96% Does the media refer more to SCLP or APTA? In the previous week, Aptamer Group had 3 more articles in the media than Scancell. MarketBeat recorded 5 mentions for Aptamer Group and 2 mentions for Scancell. Aptamer Group's average media sentiment score of 1.00 beat Scancell's score of 0.38 indicating that Aptamer Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scancell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptamer Group 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SCLP or APTA? Scancell has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500. SummaryAptamer Group beats Scancell on 7 of the 12 factors compared between the two stocks. Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£29.67M£236.99M£5.87B£2.58BDividend YieldN/A3.78%5.68%5.30%P/E Ratio-392.8641.0874.525,410.64Price / Sales24.424,994.02549.7896,691.09Price / CashN/A13.1937.5627.93Price / Book5.15103.7512.167.76Net Income-£14.17M-£90.99M£3.28B£5.89B7 Day Performance10.00%2.71%0.87%6.47%1 Month Performance71.61%21.05%4.96%55.91%1 Year Performance370.09%530.95%60.74%147.81% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 1.10flatN/A+358.3%£29.67M£1.22M-392.8637News CoveragePositive NewsInsider TradeSCLPScancellN/AGBX 8.87-1.4%N/A-43.0%£92.09MN/A-426.6351News CoverageEarnings ReportHigh Trading VolumeMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownHVOhVIVO1.7742 of 5 starsGBX 10.10+1.0%GBX 28+177.2%-66.3%£69.41M£62.73M651.61N/ANews CoverageORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 15+1.7%N/A+31.4%£38.82M£2.68M-1,200.0011HEMOHemogenyx PharmaceuticalsN/AGBX 758+26.3%N/A+63,025.0%£34.82MN/A-418.5514Gap DownHigh Trading VolumeCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading Volume Related Companies and Tools Related Companies Scancell Alternatives Mereo BioPharma Group plc (MPH.L) Alternatives hVIVO Alternatives Open Orphan Alternatives Redx Pharma Alternatives e-therapeutics Alternatives SkinBioTherapeutics Alternatives Hemogenyx Pharmaceuticals Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:APTA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTA Stock Alerts